DSM-Firmenich AG
DSFIR: XAMS (NLD)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|xD | LOCK|&rm | LOCK|TSFQXZ |
DSM-Firmenich Earnings: Sales Growth Slows on Heightened Customer Caution; Shares Attractive
DSM-Firmenich reported a slowdown in third-quarter organic sales growth to 2% due to more cautious customer behavior. Full-year EBITDA guidance was lowered by EUR 100 million to EUR 2.3 billion, reflecting a larger currency headwind and a weaker-than-expected improvement in vitamins.
